Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

HIV-1 vaccines and adaptive trial designs.

Corey L, Nabel GJ, Dieffenbach C, Gilbert P, Haynes BF, Johnston M, Kublin J, Lane HC, Pantaleo G, Picker LJ, Fauci AS.

Sci Transl Med. 2011 Apr 20;3(79):79ps13. doi: 10.1126/scitranslmed.3001863.

2.

Predictive value of primate models for AIDS.

Haigwood NL.

AIDS Rev. 2004 Oct-Dec;6(4):187-98. Review.

PMID:
15700617
3.

Complex immune correlates of protection in HIV-1 vaccine efficacy trials.

Tomaras GD, Plotkin SA.

Immunol Rev. 2017 Jan;275(1):245-261. doi: 10.1111/imr.12514. Review.

PMID:
28133811
4.

Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.

Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC.

Nat Med. 2008 Jun;14(6):617-21. doi: 10.1038/nm.f.1759.

5.

The design and evaluation of HIV-1 vaccines.

Saunders KO, Rudicell RS, Nabel GJ.

AIDS. 2012 Jun 19;26(10):1293-302. doi: 10.1097/QAD.0b013e32835474d2. Review.

PMID:
22706011
6.

New clinical trial designs for HIV vaccine evaluation.

Moodie Z, Janes H, Huang Y.

Curr Opin HIV AIDS. 2013 Sep;8(5):437-42. doi: 10.1097/COH.0b013e328363d46a. Review.

7.

HIV vaccine development at the turn of the 21st century.

Girard MP, Plotkin SA.

Curr Opin HIV AIDS. 2012 Jan;7(1):4-9. doi: 10.1097/COH.0b013e32834ddc96. Review.

PMID:
22156840
8.

Efficacy of AIDS vaccine strategies in nonhuman primates.

Uberla K.

Med Microbiol Immunol. 2005 Aug;194(4):201-6. Epub 2005 Apr 21. Review.

PMID:
15843997
9.

Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.

Girard MP, Osmanov S, Assossou OM, Kieny MP.

Vaccine. 2011 Aug 26;29(37):6191-218. doi: 10.1016/j.vaccine.2011.06.085. Epub 2011 Jun 28. Review.

PMID:
21718747
10.

Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.

Rolland M, Gilbert P.

AIDS Res Hum Retroviruses. 2012 Apr;28(4):400-4. doi: 10.1089/AID.2011.0240. Epub 2011 Sep 27.

11.

Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.

Page M, Stebbings R, Berry N, Hull R, Ferguson D, Davis L, Duffy L, Elsley W, Hall J, Ham C, Hassall M, Li B, Mee ET, Quartey-Papafio R, Rose NJ, Mathy N, Voss G, Stott EJ, Almond N.

Retrovirology. 2012 Jul 16;9:56. doi: 10.1186/1742-4690-9-56.

12.

Prospects for a globally effective HIV-1 vaccine.

Excler JL, Robb ML, Kim JH.

Vaccine. 2015 Nov 27;33 Suppl 4:D4-12. doi: 10.1016/j.vaccine.2015.03.059. Epub 2015 Jun 20. Review.

PMID:
26100921
13.

Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.

Haut LH, Ertl HC.

J Leukoc Biol. 2009 Oct;86(4):779-93. doi: 10.1189/jlb.0209094. Epub 2009 Jul 13. Review.

PMID:
19597003
14.

New directions for HIV vaccine development from animal models.

McChesney MB, Miller CJ.

Curr Opin HIV AIDS. 2013 Sep;8(5):376-81. doi: 10.1097/COH.0b013e328363d3a2. Review.

15.

Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.

Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, DeSilva V, Fritts L, Bett AJ, Casimiro DR, Shiver JW, Robert-Guroff M, Robertson MN, McChesney MB, Gilbert PB, Miller CJ.

J Virol. 2012 Feb;86(4):2239-50. doi: 10.1128/JVI.06175-11. Epub 2011 Dec 7.

16.

Vaccine development against HIV-1: current perspectives and future directions.

Edgeworth RL, San JH, Rosenzweig JA, Nguyen NL, Boyer JD, Ugen KE.

Immunol Res. 2002;25(1):53-74. Review.

PMID:
11868934
17.

Progress toward an HIV vaccine.

Letvin NL.

Annu Rev Med. 2005;56:213-23. Review.

PMID:
15660510
18.

Particle-based vaccines for HIV-1 infection.

Young KR, Ross TM.

Curr Drug Targets Infect Disord. 2003 Jun;3(2):151-69. Review.

PMID:
12769792
19.

Progress in HIV-1 vaccine development.

Haynes BF, McElrath MJ.

Curr Opin HIV AIDS. 2013 Jul;8(4):326-32. doi: 10.1097/COH.0b013e328361d178. Review.

20.

No acquisition: a new ambition for HIV vaccine development?

Lakhashe SK, Silvestri G, Ruprecht RM.

Curr Opin Virol. 2011 Oct;1(4):246-53. doi: 10.1016/j.coviro.2011.07.005. Review.

Supplemental Content

Support Center